Objective To investigate the clinical response and security of dinutuximab β immunotherapy in neuroblastoma children. Methods A retrospective analysis was performed on 13 children who received dinutuximab β immunotherapy in our hospital since 2022 to evaluate the adverse reactions, tolerability, safety and short-term efficacy during treatment. Result During the treatment of dinutuximab β, the main adverse reactions were fever, pain, gastrointestinal reactions (diarrhea/nausea/vomiting), capillary leakage syndrome, ocular toxicity, bronchospasm, rash, hematological toxicity and infection, which were basically grade 3 and below. After symptomatic treatment with some common drugs or adjustment of the infusion rate of dinutuximab β, it can be effectively alleviated with high security. With the advance of treatment cycle, the incidence of various side effects decreased, and the patients had a good tolerance to treatment. Conclusion The use of dinutuximab β immunotherapy for pediatric neuroblastoma has good safety and tolerability, and the adverse reactions gradually decrease or disappear with the increase of treatment cycle.